Lung mesenchymal cells and the application of compounds in lung epithelial cells and lung organoids

By preparing and using BDNF-expressing lung interstitial cell compositions and adding BDNF protein to lung epithelial organoid culture medium, the problem of unknown interstitial cell role during human lung organogenesis was solved, and the survival of lung epithelial cells was significantly improved. and branch formation, achieving improvement of the microenvironment of lung cells.

CN116622626BActive Publication Date: 2024-11-12GUANGZHOU NAT LAB
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202310423683.0
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2023-04-18
Publication Date
2024-11-12
Estimated Expiration
2043-04-18

AI Technical Summary

Technical Problem

The prior art has failed to determine the key role of interstitial cells in human lung organogenesis and their role in promoting the development and specialization of human lung epithelial cells, and it has not been clarified whether substitution of cell population functions can be achieved through compounds.

Method used

Provide a preparation method and composition for lung interstitial cells. By culturing pluripotent stem cells in culture medium and isolating lung interstitial cells expressing BDNF, a composition that can promote the survival, proliferation and differentiation of lung epithelial cells is prepared, and BDNF protein or its promoter is added in lung epithelial organoid culture medium to improve survival and branching formation of lung epithelial cells.

Benefits of technology

It significantly promotes the survival of human lung organoids and the proportion of branching of lung epithelial cells, improves the proliferation and differentiation of lung epithelial cells, and provides products for improving the microenvironment of lung cells or tissues.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN116622626B_ABST
    Figure CN116622626B_ABST
Patent Text Reader

Abstract

The present application discloses the use of pulmonary mesenchymal cells and compounds in pulmonary epithelial cells and pulmonary organoids. In the first aspect of the present application, the use of BDNF protein or BDNF promoter in the preparation of pulmonary epithelial organoids, products that promote the survival and / or branching of pulmonary epithelial organoids, products that promote the proliferation and / or regeneration of pulmonary cells or tissues, and products that promote the repair and / or regeneration of pulmonary organs or trachea is provided.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present application relates to the technical field of lung epithelial cells, and in particular to the application of lung mesenchymal cells and compounds in lung epithelial cells and lung organoids. Background Art

[0002] Different types of interstitial cells, including mesenchymal cells (MSCs), have broad prospects for translational applications and can be used to improve the in vivo cell transplantation microenvironment, immune regulation, and in vitro cell culture, cell therapy, and organoid induction, etc. At different stages of human lung development, there are various types of interstitial cells, which play an important regulatory and supporting role in the development and functional specialization of lung epithelial cells and the regulation of the in vivo lung microenvironment. In the field of biomedical research, it has been reported that there are LGR5-positive interstitial cell populations in the adult lung (Kadur Lakshminarasimha Murthy, P. et al. Human distal lung maps and lineage hierarchies reveal a bipotent progenitor. Nature, (2022).), and NOTUM-positive interstitial cell populations in the embryonic period (Lim, K. et al. Organoid modeling of human fetal lung alveolar development reveals mechanisms of cell fatepatterning and neonatal respiratory disease. Cell Stem Cell 30, 20-37 (2023).), which play an important role in the functional specialization and maturation of distal basal cells and alveolar epithelial cells AT2, respectively.

[0003] However, these studies have not identified the mesenchymal cells that play a key role in human lung organogenesis, especially the mesenchymal cells that can promote the development of human lung epithelial cells and the specialization of proximal and distal epithelial cells during human lung organogenesis. Moreover, since the key mesenchymal cells are uncertain, it is unclear whether the function of a part of the cell population can be replaced by compounds. Summary of the invention

[0004] The present application aims to solve at least one of the technical problems existing in the prior art. To this end, the present application proposes the use of a pulmonary mesenchymal cell and a compound in pulmonary epithelial cells and pulmonary organoids. This compound can effectively promote the survival of human pulmonary organoids and increase the proportion of branching formation of pulmonary epithelial organoids.

[0005] In a first aspect of the present application, a method for preparing pulmonary interstitial cells is provided, the preparation method comprising the following steps:

[0006] Cultivating pluripotent stem cells in culture medium to obtain lung mesenchymal cells;

[0007] Lung interstitial cells expressing BDNF were isolated.

[0008] In a second aspect of the present application, a composition is provided, the composition comprising any of the aforementioned pulmonary interstitial cells, or the raw material for preparing the composition comprises any of the aforementioned pulmonary interstitial cells. The composition prepared using any of the aforementioned pulmonary interstitial cells as the raw material for preparing the composition can specifically be the supernatant obtained by culturing the aforementioned pulmonary interstitial cells, or a concentrated product of the supernatant, or a dried product of the supernatant, or a product obtained by using the aforementioned products as active ingredients and adding ingredients, additives, and the like commonly used in the art.

[0009] The third aspect of the present application provides the use of any of the aforementioned pulmonary mesenchymal cells, or any of the aforementioned compositions, in the preparation of a product that promotes the survival, proliferation, differentiation of pulmonary epithelial cells or improves the microenvironment of pulmonary cells or tissues.

[0010] In some embodiments of the present application, differentiation includes at least one of proximal differentiation and distal differentiation.

[0011] In some embodiments of the present application, the proximal and distal differentiation of lung epithelial cells includes differentiation of lung epithelial cells into proximal lung epithelial cells or distal lung epithelial cells.

[0012] In some embodiments of the present application, the lung epithelial cells differentiate into at least one of airway epithelium and alveolar epithelium.

[0013] In some embodiments of the present application, the lung epithelial cells are lung epithelial cells of any one of a lung epithelial cell population, a lung tissue, a lung organ, and a lung organoid.

[0014] In some embodiments of the present application, the lung epithelial cell population includes more than 2, more than 5, more than 10, more than 20, more than 50, more than 100, more than 200, more than 500, more than 1000, more than 2000, more than 5000, more than 10000, more than 20000, more than 50000, more than 1000000 lung epithelial cells. In some embodiments, the lung epithelial cell population includes 2 to 1,000,000, 2 to 500,000, 10 to 100,000, 100 to 10,000 lung epithelial cells.

[0015] In some embodiments of the present application, the lung epithelial cells include lung epithelial stem cells.

[0016] In some embodiments of the present application, lung epithelial stem cells are obtained by inducing differentiation of foregut endoderm cells.

[0017] In some embodiments of the present application, foregut endoderm cells are obtained by inducing differentiation of definitive endoderm cells.

[0018] In some embodiments of the present application, the definitive endoderm cells are obtained by inducing differentiation of pluripotent stem cells.

[0019] In some embodiments of the present application, the lung organoid is a lung epithelial organoid.

[0020] The fourth aspect of the present application provides the use of BDNF protein or BDNF promoter in the preparation of lung epithelial organoids, products that promote the survival and / or branching of lung epithelial organoids, products that promote the proliferation and / or regeneration of lung cells or tissues, and products that promote the repair and / or regeneration of lung organs or trachea.

[0021] In some embodiments of the present application, the BDNF promoter includes a substance that increases the expression or activity of BDNF at the protein or gene level.

[0022] In some embodiments of the present application, the BDNF promoter includes at least one of a nucleic acid molecule, an expression cassette, a recombinant vector, a recombinant cell, a protein, and a small molecule compound that increases the expression or activity of BDNF.

[0023] In some embodiments of the present application, the BDNF promoter includes at least one of an endogenous promoter and an exogenous promoter.

[0024] In some embodiments of the present application, the BDNF promoter includes a substance that specifically knocks in the BDNF gene, a substance that specifically upregulates the mRNA level of BDNF, a substance that specifically promotes the protein expression level of BDNF, a substance that specifically increases the activity of BDNF protein, or a vector containing any of the foregoing.

[0025] In some embodiments of the present application, the substance for specifically knocking in the BDNF gene includes at least one of CRISPR / Cas, ZFN, TALEN, and Cre-LoxP.

[0026] In a fifth aspect of the present application, a method for preparing lung epithelial organoids is provided, the method comprising the step of culturing lung epithelial cells in a lung epithelial organoid culture medium, wherein BDNF is added to the lung organoid culture medium.

[0027] In some embodiments of the present application, the lung epithelial organoid culture medium includes 1-1000ng / ml, 10-800ng / ml, 50-500ng / ml, 100-300ng / ml, 150-250ng / ml of BDNF, for example, it can be 1ng / ml, 2ng / ml, 5ng / ml, 10ng / ml, 20ng / ml, 50ng / ml, 100ng / ml, 150ng / ml, 200ng / ml, 250ng / ml, 300ng / ml, 400ng / ml, 500ng / ml, 600ng / ml, 700ng / ml, 800ng / ml, 900ng / ml, 1000ng / ml of BDNF.

[0028] In some embodiments of the present application, the lung epithelial organoid culture medium comprises:

[0029] Ⅰ. Basic culture medium;

[0030] II, BDNF;

[0031] III. At least one of cell growth factor, L-glutamine additive, Wnt pathway small molecule inhibitor, thioglycerol, B27, N2 and Vc.

[0032] In some embodiments of the present application, the basal culture medium includes at least one of MEM, α-MEM, G-MEM, IMDM, DMEM, F10, F12, DMEM / F12, RPMI1640, etc.

[0033] In some embodiments of the present application, the cell growth factor includes at least one of keratinocyte growth factor (KGF), fibroblast growth factor 10 (FGF10), and the like.

[0034] In some embodiments of the present application, the lung epithelial organoid culture medium includes 0-50 ng / ml KGF and 0-50 ng / ml FGF10. In some embodiments, the lung epithelial organoid culture medium includes 1-50 ng / ml, 2-40 ng / ml, 3-30 ng / ml, 5-20 ng / ml, 5-15 ng / ml KGF and 1-50 ng / ml, 2-40 ng / ml, 3-30 ng / ml, 5-20 ng / ml, 5-15 ng / ml FGF10.

[0035] In some embodiments of the present application, the L-glutamine additive refers to a substance containing L-glutamine or reacting (such as hydrolysis, etc.) to generate L-glutamine during the culture process, including at least one of L-glutamine and L-glutamine dipeptide.

[0036] In some embodiments of the present application, the dipeptide of L-glutamine includes at least one of alanyl L-glutamine and glycyl L-glutamine.

[0037] In some embodiments of the present application, the lung epithelial organoid culture medium includes alanyl-L-glutamine (GlutaMax).

[0038] In some embodiments of the present application, the lung epithelial organoid culture medium includes 1-5 mM, 1-4 mM, or 1-3 mM alanyl-L-glutamine.

[0039] In some embodiments of the present application, the small molecule inhibitor of the Wnt pathway includes at least one of CHIR99021 and XAV939.

[0040] In some embodiments of the present application, the lung epithelial organoid culture medium includes at least one of 1 to 10 μM CHIR99021 and 1 to 10 μM XAV939.

[0041] In some embodiments of the present application, the lung epithelial organoid culture medium includes 1-10 μM, 1-8 μM, 1-5 μM, or 2-4 μM CHIR99021.

[0042] In some embodiments of the present application, the lung epithelial organoid culture medium includes 1-1000 μM, 10-900 μM, 50-800 μM, 100-700 μM, 200-600 μM, 300-500 μM, or 350-450 μM thioglycerol.

[0043] In some embodiments of the present application, B27 is B27 containing all ingredients (for example, it may contain vitamin A).

[0044] In some embodiments of the present application, the lung epithelial organoid culture medium includes 1× to 50× B27.

[0045] In some embodiments of the present application, the lung epithelial organoid culture medium includes 1× to 50× N2.

[0046] In some embodiments of the present application, the lung epithelial organoid culture medium includes 1-100 μg / ml, 10-90 μg / ml, 20-80 μg / ml, 30-70 μg / ml, 40-60 μg / ml of Vc.

[0047] In some embodiments of the present application, the lung epithelial organoid culture medium includes basal culture medium, BDNF, KGF, FGF10, GlutaMax, CHIR99021, thioglycerol, B27, N2 and Vc.

[0048] In some embodiments of the present application, the lung epithelial organoid culture medium includes basal culture medium, 1-1000 ng / ml BDNF, 1-50 ng / ml KGF, 1-50 ng / ml FGF10, 1-5 mM GlutaMax, 1-10 μM CHIR99021, 1-1000 μM thioglycerol, 1×-50× B27, 1×-50× N2 and 1-100 μg / ml Vc.

[0049] In some embodiments of the present application, the lung epithelial cells include lung epithelial stem cells.

[0050] In some embodiments of the present application, lung epithelial stem cells are obtained by inducing differentiation of foregut endoderm cells.

[0051] In some embodiments of the present application, lung epithelial stem cells are obtained by inducing differentiation of foregut endoderm cells using a lung epithelial stem cell induction medium, which includes a basal culture medium, and at least one of cell growth factors, L-glutamine additives, Wnt pathway small molecule inhibitors, thioglycerol, B27, N2, BMP4, RA and Vc.

[0052] In some embodiments of the present application, the lung epithelial stem cell induction medium includes basal medium, 1-50 ng / ml KGF, 1-50 ng / ml FGF10, 1-5 mM GlutaMax, 1-10 μM CHIR99021, 1-1000 μM thioglycerol, 1-50 ng / ml BMP4, 0.01-1 μM RA, 1×-50× B27, 1×-50× N2 and 1-100 μg / ml Vc.

[0053] In some embodiments of the present application, foregut endoderm cells are obtained by inducing differentiation of definitive endoderm cells.

[0054] In some embodiments of the present application, foregut endoderm cells are obtained by inducing differentiation of definitive endoderm cells using a foregut endoderm cell differentiation induction medium.

[0055] In some embodiments of the present application, the foregut endoderm cell differentiation induction medium includes a basal medium and at least one of an L-glutamine additive, thioglycerol, B27, N2, SB431542, SAG, Noggin, IWP-2 and Vc.

[0056] In some embodiments of the present application, the foregut endoderm cell induction differentiation medium includes basal culture medium, 1-5mM GlutaMax, 1-1000μM thioglycerol, 1-100μM SB431542, 0.1-10μM SAG, 1-500ng / ml Noggin, 1-10μM IWP-2, 1×-50× B27, 1×-50× N2 and 1-100μg / ml Vc.

[0057] In some embodiments of the present application, the definitive endoderm cells are obtained by inducing differentiation of pluripotent stem cells.

[0058] In some embodiments of the present application, the definitive endoderm cells are obtained by inducing differentiation of pluripotent stem cells using a definitive endoderm cell differentiation induction medium.

[0059] In some embodiments of the present application, the medium for inducing differentiation of definitive endoderm cells comprises a basal medium and at least one of a small molecule inhibitor of the Wnt pathway, Activin A and Y27632.

[0060] In some embodiments of the present application, the medium for inducing differentiation of definitive endoderm cells comprises a basal medium and at least one of 1-10 μM CHIR99021, 1-500 μg / ml Activin A and 1-100 μM Y27632.

[0061] In a sixth aspect of the present application, a lung epithelial organoid culture medium is provided, wherein the lung epithelial organoid culture medium comprises BDNF.

[0062] In some embodiments of the present application, the lung epithelial organoid culture medium includes 1-1000ng / ml, 10-800ng / ml, 50-500ng / ml, 100-300ng / ml, 150-250ng / ml of BDNF, for example, it can be 1ng / ml, 2ng / ml, 5ng / ml, 10ng / ml, 20ng / ml, 50ng / ml, 100ng / ml, 150ng / ml, 200ng / ml, 250ng / ml, 300ng / ml, 400ng / ml, 500ng / ml, 600ng / ml, 700ng / ml, 800ng / ml, 900ng / ml, 1000ng / ml of BDNF.

[0063] In some embodiments of the present application, the lung epithelial organoid culture medium comprises:

[0064] Ⅰ. Basic culture medium;

[0065] II, BDNF;

[0066] III. At least one of cell growth factor, L-glutamine additive, Wnt pathway small molecule inhibitor, thioglycerol, B27, N2 and Vc.

[0067] In some embodiments of the present application, the basal culture medium includes at least one of MEM, α-MEM, G-MEM, IMDM, DMEM, F10, F12, DMEM / F12, RPMI1640, etc.

[0068] In some embodiments of the present application, the cell growth factor includes at least one of keratinocyte growth factor (KGF), fibroblast growth factor 10 (FGF10), and the like.

[0069] In some embodiments of the present application, the lung epithelial organoid culture medium includes 0-50 ng / ml KGF and 0-50 ng / ml FGF10. In some embodiments, the lung epithelial organoid culture medium includes 1-50 ng / ml, 2-40 ng / ml, 3-30 ng / ml, 5-20 ng / ml, 5-15 ng / ml KGF and 1-50 ng / ml, 2-40 ng / ml, 3-30 ng / ml, 5-20 ng / ml, 5-15 ng / ml FGF10.

[0070] In some embodiments of the present application, the L-glutamine additive refers to a substance containing L-glutamine or reacting (such as hydrolysis, etc.) to generate L-glutamine during the culture process, including at least one of L-glutamine and L-glutamine dipeptide.

[0071] In some embodiments of the present application, the dipeptide of L-glutamine includes at least one of alanyl L-glutamine and glycyl L-glutamine.

[0072] In some embodiments of the present application, the lung epithelial organoid culture medium includes alanyl-L-glutamine (GlutaMax).

[0073] In some embodiments of the present application, the lung epithelial organoid culture medium includes 1-5 mM, 1-4 mM, or 1-3 mM alanyl-L-glutamine.

[0074] In some embodiments of the present application, the small molecule inhibitor of the Wnt pathway includes at least one of CHIR99021 and XAV939.

[0075] In some embodiments of the present application, the lung epithelial organoid culture medium includes at least one of 1 to 10 μM CHIR99021 and 1 to 10 μM XAV939.

[0076] In some embodiments of the present application, the lung epithelial organoid culture medium includes 1-10 μM, 1-8 μM, 1-5 μM, or 2-4 μM CHIR99021.

[0077] In some embodiments of the present application, the lung epithelial organoid culture medium includes 1-1000 μM, 10-900 μM, 50-800 μM, 100-700 μM, 200-600 μM, 300-500 μM, or 350-450 μM thioglycerol.

[0078] In some embodiments of the present application, B27 is B27 containing all ingredients (for example, it may contain vitamin A).

[0079] In some embodiments of the present application, the lung epithelial organoid culture medium includes 1× to 50× B27.

[0080] In some embodiments of the present application, the lung epithelial organoid culture medium includes 1× to 50× N2.

[0081] In some embodiments of the present application, the lung epithelial organoid culture medium includes 1-100 μg / ml, 10-90 μg / ml, 20-80 μg / ml, 30-70 μg / ml, 40-60 μg / ml of Vc.

[0082] In some embodiments of the present application, the lung epithelial organoid culture medium includes basal culture medium, BDNF, KGF, FGF10, GlutaMax, CHIR99021, thioglycerol, B27, N2 and Vc.

[0083] In some embodiments of the present application, the lung epithelial organoid culture medium includes basal culture medium, 1-1000 ng / ml BDNF, 1-50 ng / ml KGF, 1-50 ng / ml FGF10, 1-5 mM GlutaMax, 1-10 μM CHIR99021, 1-1000 μM thioglycerol, 1×-50× B27, 1×-50× N2 and 1-100 μg / ml Vc.

[0084] In a seventh aspect of the present application, a lung epithelial organoid is provided, which is prepared using the aforementioned preparation method.

[0085] The eighth aspect of the present application provides the use of the aforementioned lung epithelial organoids in the preparation of developmental model products, disease model products, organ regeneration or repair products, and drug testing or screening products.

[0086] In some embodiments of the present application, the developmental model product includes any one of a lung development model, an alveolar development model, an airway development model, a tracheal development model, a bronchial development model, a lung alveolar development, a lung lobe model, and the like.

[0087] In some embodiments of the present application, the disease model product includes at least one of a cystic pulmonary fibrosis model, an idiopathic pulmonary fibrosis model, an asthma model, a chronic obstructive pulmonary disease model, a viral infection model, a lung cancer model, and the like.

[0088] In some embodiments of the present application, the organ regeneration or repair product includes a product for replacing or repairing damaged or diseased lung tissue or lung, or a product for promoting the regeneration or development of lung cells, tissues, or trachea.

[0089] In some embodiments of the present application, drug testing or screening products include products for verifying the pharmacokinetic toxicity and efficacy of new drugs in the lungs or lung tissues, or other drug response tests, thereby completing drug screening.

[0090] Additional aspects and advantages of the present application will be given in part in the description below, and in part will become apparent from the description below, or will be learned through the practice of the present application. BRIEF DESCRIPTION OF THE DRAWINGS

[0091] Figure 1 In Example 1 of the present application, human pluripotent stem cell directed differentiation technology and 3D culture technology were used to detect the effect of BDNF on the induction and growth of lung epithelial organoids. Among them, A is the preparation process of lung epithelial organoids, B is the photos of lung epithelial organoids in the experimental group and the control group on the 2nd and 10th day of induction observation, and C is the proportion of lung epithelial organoids with branches in the experimental group and the control group on the 10th day of induction observation.

[0092] Figure 2 It is the immunofluorescence staining result of the lung epithelial organoid in Example 1 of the present application. Among them, A and B are the immunofluorescence staining results of different branches of the lung epithelial organoid. DETAILED DESCRIPTION

[0093] The following will clearly and completely describe the concept of the present application and the technical effects produced in combination with the embodiments, so as to fully understand the purpose, features and effects of the present application. Obviously, the described embodiments are only part of the embodiments of the present application, not all of them. Based on the embodiments of the present application, other embodiments obtained by those skilled in the art without creative work are all within the scope of protection of the present application.

[0094] The embodiments of the present application are described in detail below. The described embodiments are exemplary and are only used to explain the present application, and should not be understood as limiting the present application.

[0095] In the description of this application, "several" means more than one, "more" means more than two, "greater than", "less than", "exceed", etc. are understood to exclude the number itself, and "above", "below", "within", etc. are understood to include the number itself. If there is a description of "first" or "second", it is only used for the purpose of distinguishing technical features, and cannot be understood as indicating or implying relative importance or implicitly indicating the number of the indicated technical features or implicitly indicating the order of the indicated technical features.

[0096] Unless otherwise defined, all technical and scientific terms used in this application have the same meaning as those commonly understood by those skilled in the art to which this application belongs. The terms used herein are only for the purpose of describing the embodiments of this application and are not intended to limit this application.

[0097] In the description of the present application, the description with reference to the terms "one embodiment", "some embodiments", "illustrative embodiments", "examples", "specific examples" or "some examples" means that the specific features, structures, materials or characteristics described in conjunction with the embodiment or example are included in at least one embodiment or example of the present application. In this specification, the schematic representation of the above terms does not necessarily refer to the same embodiment or example. Moreover, the specific features, structures, materials or characteristics described may be combined in any one or more embodiments or examples in a suitable manner.

[0098] The following is an explanation with reference to specific examples. Some of the experimental methods involved in the following embodiments are as follows:

[0099] Single molecule FISH:

[0100] Take freshly embedded sample slices, dry at room temperature, fix with 4% PFA for 10 minutes, wash with PBS 3 times, 5 minutes each time, and then permeabilize with 70% alcohol at room temperature for more than 1 hour. Take out the slices, wipe off the excess alcohol, dry slightly, draw a hydrophobic circle with an immunohistochemistry pen, add washing solution in the circle, and shake at room temperature for 5 to 15 minutes to rehydrate. Remove the washing solution, add the hybridization solution containing the probe, and then place the slide in a wet box and incubate at 37°C for 4 to 16 hours. Take out the wet box, remove the hybridization solution, wash with washing solution and 37°C for 30 minutes, repeat 2 times. Take out the wet box and incubate DAPI at room temperature to mark the cell nucleus. Remove DAPI, wash with PBS for 5 minutes, seal the slide with anti-fading sealing agent, and store in the dark. Observe the FISH results under a fluorescence microscope.

[0101] Immunofluorescence staining:

[0102] Take freshly embedded sample slices, dry at room temperature, fix with 4% PFA for 10 minutes, wash with PBS 3 times, 5 minutes each time, then permeabilize with 0.5% Triton for 20 minutes, and block with 5% BSA for 1 hour. Incubate with primary antibody at 4°C overnight; wash with PBS 3 times, 10 minutes each time; incubate with secondary antibody at room temperature for 2 hours; wash with PBS 2 times, 5 minutes each time; incubate with DAPI for 5 minutes; wash with PBS 2 times, 5 minutes each time. Seal with anti-fading sealant and store in the dark. Observe the results under a fluorescence microscope.

[0103] Example 1: Role of BDNF in Inducing Differentiation of Lung Epithelial Organoids

[0104] refer to Figure 1 The preparation process of lung epithelial organoids shown in A is as follows:

[0105] (1) Human pluripotent stem cells were placed in a well plate coated with Matrigel and cultured with mTeSR1. When the confluence reached 90%-100%, they were washed once with preheated RPMI1640 medium, and definitive endoderm cell differentiation induction medium was added. The induction medium was replaced every day for 3 days.

[0106] (2) After 3 days, wash the cells once with pre-warmed DMEM / F12 medium and replace with foregut endoderm cell differentiation medium. Change the medium every 2 days for a total of 4 days.

[0107] (3) After 4 days, the lung epithelial stem cell induction medium was replaced. The cells were washed with DMEM / 12 before the medium change. The medium was changed every 2 days for a total of 7-8 days.

[0108] (4) Around day 14, epithelial cell colonies were picked and 10 to 15 epithelial cell colonies were embedded in 50 μl of Matrigel. Lung epithelial organoid culture medium was then added for induction and observation. The medium was changed every 2 days.

[0109] During the above experiments, the specific compositions of each culture medium are as follows:

[0110] Definitive endoderm cell differentiation medium: RPMI 1640 + Activin A (100 ng / ml) + CHIR99021 (2 μM) + Y27632 (10 μM).

[0111] Foregut endoderm cell induction differentiation medium: DMEM / F12+GlutaMax(1×)+B27(1×)+N2(1×)+Vc(50μg / ml)+MTG(0.4mM)+SB431542(10μM)+SAG(1μM)+Noggin(100ng / ml) / IWP-2(2μM).

[0112] Lung epithelial stem cell induction medium: DMEM / F12+GlutaMax(1×)+B27(1×)+N2(1×)+Vc(50μg / ml)+MTG(0.4mM)+CHIR99021(3μM)+KGF(10ng / ml)+FGF10(10ng / ml)+BMP4(20ng / ml)+RA(0.1μM).

[0113] Lung epithelial organoid culture medium: DMEM / F12+GlutaMax(1×)+B27(1×)+N2(1×)+Vc(50μg / ml)+MTG(0.4mM)+CHIR99021(3μM)+KGF(10ng / ml)+FGF10(10ng / ml).

[0114] Among them, the experimental group (BDNF) added additional BDNF (200ng / ml) to the lung epithelial organoid culture medium compared to the control group (Ctrl).

[0115] The results are as follows Figure 1 As shown in B and C, according to Figure 1 B. The size of the lung epithelial organoids in the experimental group was much larger than that in the control group, and obvious branches were formed. Figure 1 C. Among these induced lung epithelial organoids, the proportion of organoids forming branches in the experimental group was much higher than that in the control group. Therefore, BDNF can significantly promote the survival of human lung epithelial organoids and effectively improve the branching formation of human lung epithelial organoids.

[0116] The present application is described in detail above in conjunction with the embodiments, but the present application is not limited to the above embodiments, and various changes can be made within the knowledge of ordinary technicians in the relevant technical field without departing from the purpose of the present application. In addition, the embodiments of the present application and the features in the embodiments can be combined with each other without conflict.

Claims

1. Application of BDNF protein in the preparation of products that promote branching of lung epithelial organoids.

2. The use according to claim 1, characterized in that: The product includes 100-300 ng / mL of BDNF.

3. The use according to claim 1 or 2, characterized in that: The products include Ⅰ to Ⅲ: Ⅰ. Basic culture medium; II, BDNF; III. At least one of cell growth factor, L-glutamine additive, Wnt pathway small molecule inhibitor, thioglycerol, B27, N2 and Vc.

4. The use according to claim 3, characterized in that: The basal culture medium includes at least one of MEM, α-MEM, G-MEM, IMDM, DMEM, F10, F12, DMEM / F12, and RPMI1640; and / or, the cell growth factor includes at least one of keratinocyte growth factor and fibroblast growth factor 10; and / or, the Wnt pathway small molecule inhibitor includes at least one of CHIR99021 and XAV939.

5. A method for preparing lung epithelial organoids that promote branching, characterized in that: The method comprises the steps of culturing lung epithelial cells in a lung epithelial organoid culture medium, wherein the lung epithelial organoid culture medium is supplemented with 100-300 ng / mL of BDNF.

6. The preparation method according to claim 5, characterized in that: The lung epithelial organoid culture medium includes I to III: Ⅰ. Basic culture medium; II, BDNF; III. At least one of cell growth factor, L-glutamine additive, Wnt pathway small molecule inhibitor, thioglycerol, B27, N2 and Vc.

7. The preparation method according to claim 6, characterized in that: The basal culture medium includes at least one of MEM, α-MEM, G-MEM, IMDM, DMEM, F10, F12, DMEM / F12, and RPMI1640; and / or, the cell growth factor includes at least one of keratinocyte growth factor and fibroblast growth factor 10; and / or, the Wnt pathway small molecule inhibitor includes at least one of CHIR99021 and XAV939.

8. The preparation method according to claim 5, characterized in that: The lung epithelial cells include lung epithelial stem cells, and the preparation of the lung epithelial stem cells includes: Inducing pluripotent stem cells to differentiate into definitive endoderm cells in a definitive endoderm cell differentiation medium, Inducing the differentiation of definitive endoderm cells into foregut endoderm cells in a foregut endoderm cell differentiation medium, The foregut endoderm cells were induced to differentiate into lung epithelial stem cells in lung epithelial stem cell induction medium.

9. Use of the preparation method according to any one of claims 5 to 8 in the preparation of developmental model products, disease model products, organ regeneration or repair products, drug testing or screening products.

10. The use according to claim 9, characterized in that: The developmental model products include lung development models.

11. The use according to claim 9, characterized in that: The developmental model product includes an alveolar development model.

12. The use according to claim 9, characterized in that: The developmental model products include airway development models.

13. The use according to claim 9, characterized in that: The developmental model product includes a tracheal development model.

14. The use according to claim 9, characterized in that: The developmental model products include bronchial development models.

15. The use according to claim 9, characterized in that: The developmental model product includes a pulmonary alveolar developmental model.

16. The use according to claim 9, characterized in that: The developmental model products include lung lobe models.

17. The use according to claim 9, characterized in that: The disease model product includes at least one of a cystic pulmonary fibrosis model, an idiopathic pulmonary fibrosis model, an asthma model, a chronic obstructive pulmonary disease model, a viral infection model, and a lung cancer model.

18. The use according to claim 9, characterized in that: The organ regeneration or repair products include products for replacing or repairing damaged or diseased lung tissue or lungs, or products for promoting the regeneration or development of lung cells, tissues, or trachea.